Literature DB >> 15895112

The graft-versus-lymphoma effect: clinical review and future opportunities.

B W Butcher1, R H Collins.   

Abstract

Numerous lines of preclinical and clinical evidence support the existence of a graft-versus-leukemia effect, but less evidence supporting a comparable graft-versus-lymphoma effect exists. We review here current clinical data addressing the graft-versus-lymphoma effect, including comparisons of autologous, syngeneic, and allogeneic transplantation; responses to immunomodulation; and responses to nonmyeloablative stem cell transplantation. Despite several limitations of the data, we believe that there is sufficient evidence suggesting a significant graft-versus-lymphoma effect. In addition, we discuss approaches for clinical management of lymphoma patients, opportunities for mechanistic studies afforded by donor leukocyte infusions and nonmyeloablative transplantation, and suggestions for clinical studies to further define the magnitude and applicability of the graft-versus-lymphoma effect.

Entities:  

Mesh:

Year:  2005        PMID: 15895112     DOI: 10.1038/sj.bmt.1705008

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  13 in total

1.  Hope against hope in cancer at the end of life.

Authors:  Natalie A Pattison; Christopher Lee
Journal:  J Relig Health       Date:  2009-06-16

Review 2.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Blood Adv       Date:  2017-12-08

Review 3.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 4.  Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.

Authors:  Irtiza N Sheikh; Amr Elgehiny; Dristhi Ragoonanan; Kris M Mahadeo; Yago Nieto; Sajad Khazal
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

Review 5.  Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?

Authors:  E Klyuchnikov; U Bacher; T Kroll; T C Shea; H M Lazarus; C Bredeson; T S Fenske
Journal:  Bone Marrow Transplant       Date:  2013-05-27       Impact factor: 5.483

6.  Long-Term Results of Fludarabine/Melphalan as a Reduced-Intensity Conditioning Regimen in Mantle Cell Lymphoma: The GELTAMO Experience.

Authors:  Jorge Gayoso Cruz; Rodrigo Martino; Pascual Balsalobre; Inmaculada Heras; José Luis Piñana; David Serrano; Javier de la Serna; José Francisco Tomás; Joséa Luis Díez-Martíin; Dolores Caballero
Journal:  Ther Adv Hematol       Date:  2011-02

Review 7.  Risk assessment in haematopoietic stem cell transplantation: histocompatibility.

Authors:  Effie W Petersdorf
Journal:  Best Pract Res Clin Haematol       Date:  2007-06       Impact factor: 3.020

8.  Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience.

Authors:  Mira Romany Massoud; Paolo Fabrizio Caimi; Nicole Ferrari; Pingfu Fu; Richard Creger; Robert Fox; Joanne Carlson-Barko; Merle Kolk; Lauren Brister; Brenda Wimpfheimer Cooper; Stanton Gerson; Hillard Michael Lazarus; Marcos de Lima; Basem Magdy William
Journal:  Rev Bras Hematol Hemoter       Date:  2016-08-18

9.  iNKT cells suppress the CD8+ T cell response to a murine Burkitt's-like B cell lymphoma.

Authors:  Ryan L Bjordahl; Laurent Gapin; Philippa Marrack; Yosef Refaeli
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

10.  Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial.

Authors:  Raymund Buhmann; Stanglmaier Michael; Hess Juergen; Lindhofer Horst; Christian Peschel; Hans-Jochem Kolb
Journal:  J Transl Med       Date:  2013-07-02       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.